The recent TRINITI-1 trial (NCT02732119) differs from the others that have explored the use of mTOR inhibitors in ER+ breast cancer patients because patients in this trial were actually treated with ribociclib as part of their regimen even though they had previously progressed on a CDK4/6 inhibitor. This evidence concerns the gene MTOR and breast carcinoma.